Study on Remote Ischemic Preconditioning to Protect the Heart in Type 2 Diabetes Patients Undergoing Coronary Artery Bypass Surgery

What this Trial Is About

Researchers are evaluating the effect of remote ischemic preconditioning RIPC on protecting the heart muscle during coronary artery bypass graft CABG surgery in patients with type 2 diabetes mellitus. This clinical trial addresses the concern of heart muscle injury during CABG, which is especially significant in high-risk diabetic patients. RIPC is a low-cost, non-invasive method that may help reduce heart damage by increasing tolerance to reduced blood flow through brief, repeated cycles of limb blood flow restriction. Participants will be randomly assigned to one of two groups one group will receive RIPC before the surgery, which involves inflating a blood pressure cuff on the upper arm to 200 mmHg for 5 minutes followed by 5 minutes of deflation, repeated five times before the chest is opened. The other group will receive standard care without RIPC. This procedure is done under general anesthesia and is designed to keep participants unaware of their group assignment. During the study, researchers will monitor heart injury by measuring high-sensitivity troponin T levels at 24, 48, and 72 hours after surgery. They will also assess other outcomes such as acute kidney injury within 72 hours, the maximum dose of heart support medications used during the first 72 hours, and the length of stay in the intensive care unit and hospital up to 60 days. Participants will be closely observed through these assessments to understand the potential heart-protective role of RIPC in diabetic patients undergoing cardiac surgery.

Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG